The raison d'être of any R&D chief is finding a way to increase the successful translation of innovation into a rejuvenated pipeline and successful new drug launches. The R&D heads of Britain's two biggest pharma companies were asked at a recent London conference what they believe the secret in doing that is – and both agreed that in large part it lies in creating a smarter, more focused risk-taking culture within their teams.
AstraZeneca PLC's Mene Pangalos and GlaxoSmithKline PLC's Hal Barron were featured speakers at this year's FT Global Pharmaceutical...








